ABOUT

Pipeline specialized for Musculoskeletal Diseases

About US

ImmunoForge is expanding and diversifying its clinical and non-clinical pipeline, focusing on novel drug candidates for rare musculoskeletal diseases.

  • Home
  • >
  • About
  • >
  • About US

Introduction

We have a profound belief that the better the treatment, the happier the patients.

Millions of patients are suffering from thousands of rare diseases and hundreds of new intractable disorders are diagnosed every year around the world. We can challenge the development of rare disease treatments with cutting-edge technology and a sense of mission and passion. Our motivation is to meet the unmet needs in patients with rare diseases with more tolerable and effective long-term treatment.

We aim to develop first-in-class global drugs with a high probability of success through detailed action plans in candidate selection, preclinical and clinical development, and product approval.

Cutting-edge science and technology are our raw materials, and experience and passion are our tools. We believe that our endeavours will provide a lifeline to those with potentially fatal diseases and enhance the quality of life for those living with chronic conditions. We would like to express our gratitude to all those who care and support us. Your support makes us more passionate. For a better world, we will work harder.

Thank you.

Management

Sung-Min AhnMD-PhD
Translational Scientist based on his knowledge and experience as MD.
Specialty
  • Cancer genomics
  • New Drug De velopment
Major
Experience
  • Prof. Dept. of Genome Medicine and Science, Gachon Univ.
  • Director, Gacheon Institute of Genome medicine and Science, Gachon Univ. Gil Medical Center
  • A SAB member, WIN Consortium for Personalized Cancer Medicine
  • An advisory member, IBM Oncology Data Innovation Council
  • MD, College of Medicine, Ajou Univ.
  • PhD. Univ. of Melbourne (Proteogenomics)
Kiho Chang CEO MBA
A Business Developer with extensive experiencein the new drug development process.
Specialty
  • Biodrug Development
  • Global Business
Major
Experience
  • General manager of Bio division, Ahngook Pharmaceutical
  • Head of Bio division, LG Life Sciences
  • The research center, QC, Product development, Overseas business / Dong-A Pharmaceutical
  • MBA, Yonsei Univ.
  • Bs. In Life Sciences, Sogang Univ.
EunKyu Lee CTO
  • Emeritus Professor, Department of Bio nano Engineering, Hanyang University
  • Vice President of Research at Gachon University
  • Head of Basic Research Division, Korea Research Foundation
  • Senior Member of the National Academy of Engineering of Korea
Ji-Soo Kang Other Non-Executive Director
  • Director. Seoul National University College of Natural Sciences
  • New York University Sc.D.
  • National Institutes of Health, Postdoctoral researcher
  • CJ Future Management Institute Head of Department
Jim Balance CSO/President of US branch
  • PhaseBio Pharmaceuticals, Inc.
  • BioRexis Pharmaceutical Corp.,
  • Aventis Behring LLC
  • Delta Biotechnology Ltd.,
Sang-Dae Kim CFO
  • Hyundai Mobis
  • Korea Technology Investment
  • YGPlus
Shin-Won Lee CDO
  • Wyeth
  • Pfizer
  • Boryung Pharmaceutical
Soo-Jin Rhee Executive and Vice
President/Clinical RA
  • Kwangdong Pharmaceutical
  • Ministry of Food and Drug Safety
  • NeoimmuneTech, Inc.
Ji-Young Kim Executive and Vice
President/ Non-Clinical
Development
  • Glaceum Co.
  • Ltd., Erum Biotechnologies Inc.
  • Kolon Life Science Co., Ltd.
Myung-Jeom Ryu Senior Executive
Managing Director/
New Bio-drugs
  • RaND Biosciences
  • Mirusystems
  • KIST
Byung-Woong Hur Vice President/
New bio-drugs
  • Chong Kun Dang Hyojong Research Institute
  • Ahn-Gook Pharm Bioresearch Institute
  • Eubiologics

Scientific Advisory Board

Linda Greensmith Ph.D.
  • Neuromuscular diseases (Head)
  • University College London
Michael Hanna MD
  • Director (Prof.)
  • UCL Queen Square Institute of Neurology
  • University of Manchester
Tae Hwan Chung MD
  • Assistant Professor
  • Johns Hopkins University
Eun-Young Lee Professor
  • Professor of Department of Rheumatology, Seoul National University Hospital
  • Director of the Spine Oncology Center, Seoul National University Hospital

Organizational Chart

CTO
CFO
New
bio-drugs
  • Development of
    PF1802 and PF1803
  • Research on new bio-drugs
  • Bio-process and formulation
Nonclinical
development
  • Nonclinical research
  • Research planning and strategy
  • In-vitro/In-vivo test
Business
support
  • IPO & Investor Relations / Finance & Account / HR & General affairs
Business
development
  • Global business development
  • Mid- to long-term business strategy
  • Open Innovation
Clinical
Regulatory
Affairs (RA)
  • Approval RA
  • IND and clinical support
Clinical
development
  • Clinical development
  • Global development strategy

Network

Korea
  • 고려대
  • 이화여대
  • 가톨릭대
  • 가천대학교
  • 서울대병원
  • 길병원
  • 휴젤
  • 대구경북첨단의료산업진흥재단
Global
  • Tokyo Medical and Dental University (TMDU)
  • PhaseBio
  • Cytovance Biologics
  • Elasmogen
  • Syneos
Investors
  • BNH
  • 스마일게이트
  • 컴퍼니케이파트너스
  • 코리아오메가
  • 신한캐피탈
  • 퀀텀

History

Leap to Global bio venture company by securing new-drug development technology
2020
December
Orphan Drug Designation (ODD) for DMD from the FDA
October
Smilegate investment of total 2 billion KRW (approx.. $1.8M)
September
Selected as a Global Open - innovation Company by Korea Evaluation Institute of Industrial Technology Evaluation and Planning
July
Company K Partners, Korea Omega, Shinhan Capital, Quantum Ventures Korea invested total of 4 billion KRW (approx.. $3.6M)
April
Selected as a participant in the Kinase Inhibitor project of the Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation. Selected as a participant in the Polymyositis project of the Ministry of Health and Welfare.
March
Signed a technology transfer contract with Ewha Woman's University (anti-OSCAR, antibody for osteoarthritis treatment)
2019
October
Selected as a participant in stepping stone project of Ministry of SMEs and Startups (PF1802)
July
Selected as a participant in a new drug development project of Korea Drug Development Fund (KDDF) 3 billion KRW (approx. $2.7M)
March
Contracted PF1801 global licensing agreement with PhaseBio, USA
February~March
BNH, Smilegate, Company K Partners, PhaseBio invested total of 5 billion KRW (approx.. $4.5M)
2018
December
Agreed with Elasmogen (Scotland) to introduce Platform Technology
August
Selected as a participant in stepping stone project of Ministry of SMEs and Startups (RET inhibitor)
July
Selected as a participant in the candidate substance optimization project of the Daegu-Gyeongbuk New Drug Development Center (BCR-ABL1 T315I inhibitor)
February
Made government’s start-up funding business agreement
January
Transfer Kinase Inhibitors library patented technology (Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation / Gachon University)
- Venture certification & Corporate Research Institute certification
2017
December
government TIPS program agreement (development of sarcopenia treatment)
Attracted investment from Hugel
September
Acquired a patent for sarcopenia (Gachon University)
May
Established the company